Abstract: macular retinal edema is a symptom manifested by a decrease in central visual acuity, diagnosed in the case of thrombosis of the main retinal vein and its branches. For treatment, various schemes are used, including symptomatic, pathogenetic and etiotropic therapy. As a basic therapy, two main groups of drugs are used – angiogenesis inhibitors and corticosteroids. Currently, the domestic pharmaceutical market has a new drug “Ozurdex” – implant for intravitreal administration, containing in the depot capsule dexamethasone in the form of biodegradable polymer, which allocates the active substance dosed for 6 months. The combined effect of the drug is the ability to suppress simultaneously inflammation and vascular endothelial growth factor, preventing the release of prostaglandins, which are mediators of cystoid macular edema. In order to demonstrate the results of the use of a new drug for the treatment of postthrombosis retinopathy accompanied by macular edema, the article presents clinical examples confirming its high efficiency, clinical safety and prospects for use in everyday ophthalmic practice.
Keywords: postthrombosis retinopathy, macular edema, prolonged corticosteroids